O	0	6	Uptake
O	7	9	of
B-intervention	10	19	tamoxifen
O	20	22	in
O	23	34	consecutive
O	35	48	premenopausal
O	49	54	women
O	55	60	under
O	61	73	surveillance
O	74	76	in
O	77	78	a
O	79	83	high
O	83	84	-
O	84	88	risk
O	89	95	breast
O	96	102	cancer
O	103	109	clinic
O	109	110	.

O	111	121	Randomised
O	122	128	trials
O	129	131	of
O	132	141	tamoxifen
O	142	148	versus
B-control	149	156	placebo
O	157	165	indicate
O	166	170	that
O	171	180	tamoxifen
O	181	188	reduces
O	189	195	breast
O	196	202	cancer
O	203	207	risk
O	208	210	by
O	211	224	approximately
O	225	227	33
O	227	228	%
O	228	229	,
O	230	233	yet
O	234	240	uptake
O	241	243	is
O	244	247	low
O	247	248	.

O	249	262	Approximately
O	263	265	10
O	265	266	%
O	267	269	of
O	270	275	women
O	276	278	in
O	279	282	our
O	283	289	clinic
O	290	297	entered
O	298	301	the
O	302	306	IBIS
O	306	307	-
O	307	308	I
O	309	319	prevention
O	320	325	trial
O	325	326	.

O	327	329	We
O	330	336	assess
O	337	340	the
O	341	347	uptake
O	348	350	of
O	351	360	tamoxifen
O	361	363	in
O	364	365	a
O	366	377	consecutive
O	378	384	series
O	385	387	of
O	388	401	premenopausal
O	402	407	women
O	408	411	not
O	412	414	in
O	415	416	a
O	417	422	trial
O	423	426	and
O	427	434	explore
O	435	438	the
O	439	446	reasons
O	447	450	for
O	451	457	uptake
O	458	465	through
O	466	476	interviews
O	476	477	.

O	478	481	All
O	482	490	eligible
O	491	496	women
B-age	497	504	between
I-age	505	507	33
I-age	508	511	and
I-age	512	514	46
I-age	515	520	years
B-eligibility	521	523	at
I-eligibility	524	525	â‰¥
I-eligibility	525	527	17
I-eligibility	527	528	%
I-eligibility	529	537	lifetime
I-eligibility	538	542	risk
I-eligibility	543	545	of
I-eligibility	546	552	breast
I-eligibility	553	559	cancer
I-eligibility	560	563	and
I-eligibility	564	574	undergoing
I-eligibility	575	581	annual
I-eligibility	582	593	mammography
O	594	596	in
O	597	600	our
O	601	608	service
O	609	613	were
O	614	621	invited
O	622	624	to
O	625	629	take
O	630	631	a
O	632	633	5
O	633	634	-
O	634	638	year
O	639	645	course
O	646	648	of
O	649	658	tamoxifen
O	658	659	.

O	660	667	Reasons
O	668	671	for
O	672	681	accepting
O	682	683	(
O	683	684	n
O	684	685	=
O	685	687	15
O	687	688	)
O	689	691	or
O	692	701	declining
O	702	703	(
O	703	704	n
O	704	705	=
O	705	707	15
O	707	708	)
O	709	713	were
O	714	722	explored
O	723	728	using
O	729	733	semi
O	733	734	-
O	734	744	structured
O	745	755	interviews
O	755	756	.

O	757	759	Of
B-total-participants	760	764	1279
O	765	773	eligible
O	774	779	women
O	779	780	,
B-iv-bin-abs	781	784	136
O	785	786	(
B-iv-bin-percent	786	788	10
I-iv-bin-percent	788	789	.
I-iv-bin-percent	789	790	6
I-iv-bin-percent	790	791	%
O	791	792	)
B-outcome	793	800	decided
I-outcome	801	803	to
I-outcome	804	808	take
I-outcome	809	818	tamoxifen
O	818	819	.

B-outcome	820	825	Women
I-outcome	826	827	>
I-outcome	827	829	40
I-outcome	830	835	years
O	836	837	(
B-iv-bin-abs	837	839	74
O	840	843	out
O	844	846	of
B-intervention-participants	847	850	553
O	851	852	(
B-iv-bin-percent	852	854	13
I-iv-bin-percent	854	855	.
I-iv-bin-percent	855	856	4
I-iv-bin-percent	856	857	%
O	857	858	)
O	858	859	)
O	860	863	and
O	864	869	those
B-outcome	870	872	at
I-outcome	873	879	higher
I-outcome	880	883	non
I-outcome	883	884	-
I-outcome	884	888	BRCA
I-outcome	888	889	-
I-outcome	889	899	associated
I-outcome	900	904	risk
O	905	909	were
B-outcome	910	914	more
I-outcome	915	921	likely
I-outcome	922	924	to
I-outcome	925	931	accept
I-outcome	932	941	tamoxifen
O	942	943	(
B-iv-bin-abs	943	946	129
O	947	950	out
O	951	953	of
B-intervention-participants	954	958	1109
O	959	960	(
B-iv-bin-percent	960	962	11
I-iv-bin-percent	962	963	.
I-iv-bin-percent	963	964	6
I-iv-bin-percent	964	965	%
O	965	966	)
O	966	967	)
O	967	968	.

O	969	979	Interviews
O	980	991	highlighted
O	992	996	four
O	997	1003	themes
O	1004	1015	surrounding
O	1016	1024	decision
O	1025	1031	making
O	1031	1032	:
O	1033	1042	perceived
O	1043	1049	impact
O	1050	1052	of
O	1053	1057	side
O	1058	1065	effects
O	1065	1066	,
O	1067	1070	the
O	1071	1077	impact
O	1078	1080	of
O	1081	1087	others
O	1087	1088	'
O	1089	1099	experience
O	1100	1102	on
O	1103	1110	beliefs
O	1111	1116	about
O	1117	1126	tamoxifen
O	1126	1127	,
O	1128	1137	tamoxifen
O	1138	1140	as
O	1141	1142	a
O	1143	1144	'
O	1144	1150	cancer
O	1151	1155	drug
O	1155	1156	'
O	1156	1157	,
O	1158	1161	and
O	1162	1167	daily
O	1168	1176	reminder
O	1177	1179	of
O	1180	1186	cancer
O	1187	1191	risk
O	1191	1192	.

O	1193	1202	Tamoxifen
O	1203	1209	uptake
O	1210	1213	was
O	1214	1221	similar
O	1222	1224	to
O	1225	1235	previously
O	1236	1247	ascertained
O	1248	1254	uptake
O	1255	1257	in
O	1258	1259	a
O	1260	1270	randomised
O	1271	1281	controlled
O	1282	1287	trial
O	1288	1289	(
O	1289	1293	IBIS
O	1293	1294	-
O	1294	1295	I
O	1295	1296	)
O	1296	1297	.

O	1298	1306	Concerns
O	1307	1311	were
O	1312	1319	similar
O	1320	1322	in
O	1323	1328	women
O	1329	1332	who
O	1333	1336	did
O	1337	1339	or
O	1340	1343	did
O	1344	1347	not
O	1348	1354	accept
O	1355	1364	tamoxifen
O	1364	1365	.

O	1366	1374	Decision
O	1375	1381	making
O	1382	1390	appeared
O	1391	1393	to
O	1394	1396	be
O	1397	1405	embedded
O	1406	1408	in
O	1409	1412	the
O	1413	1423	experience
O	1424	1426	of
O	1427	1438	significant
O	1439	1445	others
O	1445	1446	.
